[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shandong Suncadia Medicine Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":526},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,43,61,82,103,127,146,168,190,209,228,249,270,289,310,330,351,369,388,407,427,445,466,485,505],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100640446","phase-1-a-clinical-study-of-hrs-7156-in-healthy-participants-100640446",false,"NCT07601087","A Clinical Study of HRS-7156 in Healthy Participants","A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Ascending Oral Doses of HRS-7156 in Healthy Participants","Inclusion Criteria:\n\n1. Healthy men and women aged 18 to 55 years old at informed consent signing;\n2. Male body weight ≥50 kg, female ≥45 kg; BMI 18.5 to 30 kg\u002Fm² at screening and baseline;\n3. Have no clinically significant abnormalities at screening and baseline;\n4. Fertile females and males with fertile female partners: effective contraception 2 weeks before consent, and sustained until 1 week after the last dose (abstinence or highly effective contraception); no sperm\u002Fegg donation.\n\nExclusion Criteria:\n\n1. A history or current severe diseases of multiple systems, or other diseases interfering with trial results;\n2. Severe infection, trauma, major surgery within 3 months before screening; planned surgery during the trial;\n3. Blood donation\u002Fsevere blood loss (≥400 mL) within 8 weeks, blood transfusion within 4 weeks before screening; planned blood donation during the trial;\n4. History of drug abuse\u002Fdependence; positive urine drug test at screening.Participation in other clinical trials within 3 months before screening or planned;\n5. participation during the trial; within 5 half-lives of a prior drug (whichever is longer);\n6. Smoking history (≥5 cigarettes\u002Fday) within 4 weeks before screening; inability to abstain from tobacco during the trial; positive smoke screening at screening\u002Fbaseline;\n7. Positive for HBsAg, HIV antibody, Treponema pallidum antibody or HCV antibody at screening;\n8. Special dietary requirements and inability to comply with the unified diet;\n9. Difficulty in swallowing\u002Fvenous blood collection; intolerance to intensive blood sampling;\n10. Other circumstances deemed unsuitable for trial participation by Researcher.",true,"ALL","18 Years","55 Years",{"count":22,"type":23},66,"ESTIMATED","INTERVENTIONAL",[26],"PHASE1","The purpose of this Phase I study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-7156 in healthy participants.",[29],"Heart Failure","RECRUITING","2026-06-25",{"date":33,"type":34},"2026-06-29","ACTUAL",{"date":36,"type":23},"2026-06-12",{"date":38,"type":23},"2026-07",{"name":40,"class":41},"Shandong Suncadia Medicine Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":49,"targetDuration":4,"studyType":24,"phases":51,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":60,"locationsCount":42},"100629820","phase-1-a-bioequivalence-study-of-two-formulations-of-hrs-1893-tablets-in-healthy-participants-100629820","NCT07479641","A Bioequivalence Study of Two Formulations of HRS-1893 Tablets in Healthy Participants","Inclusion Criteria:\n\n1. Subjects aged 18 to 55 years (inclusive), regardless of gender;\n2. Body mass index (BMI) between 19 and 28 kg\u002Fm² (inclusive), with body weight ≥ 50.0 kg and \\\u003C 90.0 kg for men, and ≥ 45.0 kg and \\\u003C 90.0 kg for women;\n3. No abnormalities of clinical significance are found upon comprehensive physical examination and laboratory tests, or only minor abnormalities that are deemed by the investigator not to affect the subject's eligibility for enrollment;\n4. No clinically significant abnormalities on the 12-lead ECG;\n5. The subject must understand the study procedures and methods, voluntarily agree to participate, and provide written informed consent.\n\nExclusion Criteria:\n\n1. Subjects with suspected hypersensitivity to the investigational drug or any excipient;\n2. The subject has a history of syncope;\n3. Exclusion due to blood pressure: Systolic Blood Pressure (SBP) \\>140 mmHg or \\\u003C90 mmHg; OR Diastolic Blood Pressure (DBP) \\>90 mmHg or \\\u003C60 mmHg, as determined by the investigator to be clinically significant;\n4. History of gastric or intestinal surgery that, in the investigator's judgment, may affect drug absorption;\n5. A positive result in any one of the following infectious disease screening tests during the screening period: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), treponema pallidum antibody (syphilis), or human immunodeficiency virus antibody\u002Fantigen (HIV-Ab\u002FAg);\n6. Subjects who meet any of the following criteria will be excluded: a. Smoking: Average daily cigarette consumption of more than 5 cigarettes within the 4 weeks prior to screening; b. Alcohol: Average daily alcohol intake exceeding 15 g within one week prior to screening (15 g of alcohol is equivalent to 450 mL of beer, 150 mL of wine, or 50 mL of low-alcohol spirits); c. Non-compliance: Inability or unwillingness to abstain from smoking, alcohol, and caffeine-containing foods or beverages during the screening period and the entire study duration; d. Diet: Have special dietary requirements, cannot comply with the standardized diet provided in the study, or have a history of substance abuse;\n7. History of substance abuse;\n8. Use of any prescription drugs, over-the-counter medications, or Chinese herbal medicines within 1 month prior to dosing, or the use of any drug within 5 half-lives prior to screening (whichever is longer). Additionally, subjects who plan to take any non-study medications during the trial period will be excluded;\n9. Any other circumstances that, in the investigator's judgment, make the subject unsuitable for participation in the trial. This includes physiological or psychological conditions that may increase the trial risk, affect the subject's protocol compliance, or impact the subject's ability to complete the study.",{"count":50,"type":23},58,[26],"This study will investigate the bioequivalence between two formulations of HRS-1893 tablets. Safety and tolerability will also be assessed.",[54],"Cardiomyopathy","2026-06-24",{"date":33,"type":34},{"date":58,"type":34},"2026-04-14",{"date":38,"type":23},{"name":40,"class":41},{"id":62,"slug":63,"hasResults":12,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":4,"eligibilityCriteria":67,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":68,"targetDuration":4,"studyType":24,"phases":70,"briefSummary":71,"conditions":72,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":42},"100641684","phase-1-a-study-to-assess-the-effect-of-hrs-1301-on-the-pharmacokinetics-of-midazolam-and-atorvastatin-in-healthy-participants-100641684","NCT07608705","A Study to Assess the Effect of HRS-1301 on the Pharmacokinetics of Midazolam and Atorvastatin in Healthy Participants","An Open-label, Single-arm, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HRS-1301 Tablets on the Pharmacokinetics of Midazolam and Atorvastatin Calcium Tablets in Healthy Participants","Inclusion Criteria:\n\n1. Subjects must be aged ≥ 18 years and ≤ 55 years on the day of signing the informed consent form (ICF);\n2. At screening, body mass index (BMI) must be ≥ 19.0 kg\u002Fm² and \\\u003C 28 kg\u002Fm², with body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females;\n3. Physical examination, vital signs, electrocardiogram (ECG), posteroanterior and lateral chest X-ray\u002FCT, abdominal ultrasound, and laboratory tests (including complete blood count, blood biochemistry, urinalysis, coagulation function, and thyroid function) were normal or abnormal but of no clinical significance;\n4. Female participants must not be pregnant or lactating and must have negative pregnancy test results prior to investigational drug administration; participants must have had no unprotected sexual intercourse within two weeks prior to screening; female participants of childbearing potential and male participants with partners of childbearing potential must agree to comply with the contraception requirements for the duration specified in the protocol and have no plans to donate sperm or eggs;\n5. Subjects who understand the study procedures and methods, voluntarily agree to participate in this trial, and provide written informed consent (ICF).\n\nExclusion Criteria:\n\n1. Subjects with previous medical history or current diagnosis of cardiovascular, respiratory, digestive, urinary, hematological, endocrine, infectious, immunological, malignant neoplastic, neurological, or psychiatric\u002Fmetabolic disorders\u002Fdysfunctions, or any other disease;\n2. Subjects who have gastrointestinal, hepatic, renal, or other known diseases that may affect drug absorption, distribution, metabolism, or excretion, or that may reduce compliance;\n3. Subjects who have experienced severe trauma or undergone major surgery within 3 months prior to screening, or who plan to undergo surgery during the trial period;\n4. Subjects with a history of specific allergies, or with an allergic constitution, or with known hypersensitivity to any component of the investigational drug;\n5. Subjects who have used any medication within 2 weeks prior to screening, or who are still within 5 half-lives of any medication at the time of screening;\n6. Subjects who have participated in any other clinical trial of a drug or medical device within 3 months prior to screening, or who are still within 5 half-lives of a prior investigational drug at the time of screening;\n7. Subjects who have donated blood ≥ 200 mL or experienced significant blood loss (≥ 400 mL) within 4 weeks prior to screening, or who have received a blood transfusion within 8 weeks prior to screening;\n8. Subjects who have received a live (attenuated) vaccine within 4 weeks prior to screening or plan to receive such a vaccine during the trial period.",{"count":69,"type":23},16,[26],"This phase I study in healthy participants aims to assess the pharmacokinetics of midazolam and atorvastatin when administered alone and in combination with HRS-1301, and to assess the safety of HRS-1301 when administered alone and in combination with midazolam or atorvastatin.",[73],"Hyperlipidemias","2026-06-15",{"date":76,"type":34},"2026-06-16",{"date":78,"type":34},"2026-06-08",{"date":80,"type":23},"2026-08",{"name":40,"class":41},{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":17,"sex":88,"minAge":19,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":24,"phases":92,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":102,"locationsCount":42},"100641265","phase-1-human-mass-balance-study-of-chrs-1893-100641265","NCT07656779","Human Mass Balance Study of [¹⁴C]HRS-1893","Inclusion Criteria:\n\n1. Age range: 18 - 45 years old (inclusive of the boundaries, based on the date of signing the informed consent form). Healthy male.\n2. Body Mass Index (BMI) ranging from 19 to 26 kg\u002Fm2 (including the boundary values), with a weight of ≥ 50.0 kg.\n3. After comprehensive physical examinations (including vital signs, physical examinations, etc.) and laboratory tests (such as blood routine, blood biochemistry, coagulation function, urine routine, fecal routine + occult blood, thyroid function), as well as abdominal B-ultrasound and chest anteroposterior X-ray films, no clinically significant abnormalities were found (ALT, AST, total bilirubin, direct bilirubin, creatine kinase must be \\\u003C 1.5 times the upper limit of the normal reference value, glomerular filtration rate (eGFR) \\> 90 mL\u002F(min·1.73 m2)), or the researchers judged that there were minor abnormalities that did not affect the participants' enrollment (such as hemangioma, cyst, calcification focus, nodules, etc.). Among them, abdominal B-ultrasound and chest anteroposterior X-ray films can accept the abdominal B-ultrasound or abdominal CT that can be traced within 6 months before administration, and the results of chest anteroposterior X-ray films or chest CT.\n4. The 12-lead electrocardiogram shows no clinically significant abnormalities (among which QTc Fridericia (QTcF) must be \\\u003C 450 ms).\n5. Understand the research procedures and methods, voluntarily participate in this trial, and sign the informed consent form in person.\n\nExclusion Criteria:\n\n1. Systolic blood pressure (SBP) during the screening period or baseline period: SBP ≥ 140 mmHg or \\\u003C 90 mmHg; Diastolic blood pressure (DBP): DBP ≥ 90 mmHg or \\\u003C 60 mmHg, and the clinical doctor determines that it has clinical significance.\n2. During the screening period, any one of the following infectious disease screenings - hepatitis B surface antigen, hepatitis C antibody, syphilis antibody, or human immunodeficiency virus antibody - showing any abnormal result and judged by the researcher to have clinical significance will be included.\n3. There is a history of syncope in the past.\n4. Those who have a history of allergies to drugs, foods, or the environment, or who are allergic to the test drug or any of its components.\n5. Within one month prior to taking the research drug, any prescription drugs, over-the-counter drugs, or herbal medicines were taken; those whose drug half-life was within five half-lives at the time of screening; and those who plan to take non-research trial drugs during the trial period.\n6. Select those who smoked an average of more than 5 cigarettes per day over the past 4 weeks; those who consumed an average of more than 15 grams of alcohol per day in a week (15 grams of alcohol is equivalent to 450 mL of beer or 150 mL of wine or 50 mL of low-alcohol liquor); or those whose alcohol breath test result was greater than 0 mg\u002F100 mL during the screening period; or those who refrained from smoking, drinking alcohol and consuming caffeinated foods or beverages during the screening period and the test period, and had special dietary requirements that they could not comply with the unified diet.\n7. Habitual constipation or diarrhea.\n8. Those with a history of drug use or substance abuse; or those who tested positive for drug abuse in the screening urine test during the selection process.\n9. Those who habitually consume grapefruit juice or excessive amounts of tea, coffee and\u002For caffeinated beverages, or those who are unable to quit during the trial period.\n10. Those who have a history of fainting during blood collection or blood transfusion, or who have difficulty in blood collection or cannot tolerate venipuncture for blood collection.\n11. Screen those who have participated in any clinical trials of drugs or medical devices within the past three months (the definition of participation in clinical trials is based on the participants receiving treatment with the trial drugs or medical devices).\n12. Those who received the vaccine within the previous 1 month or during the trial period or within 1 month after administration.\n13. Those who had experienced blood loss or blood donation of 400 mL within the past 3 months, or those who received blood transfusion within the past 1 month will be selected.\n14. Staff members of the research center or other individuals directly involved in the implementation of the plan.\n15. The researchers believe that there are other circumstances that make the participants unsuitable for this trial, such as those that might increase the risk of the trial, affect the participants' compliance with the protocol, or cause physical or psychological conditions that prevent them from completing the trial.","MALE","45 Years",{"count":91,"type":23},6,[26],"HRS-1893-107 is a Phase 1, single-center, non-randomized, open-label, single-dose study designed to investigate the mass balance, metabolism, and pharmacokinetics of \\[14C\\]HRS-1893. The study aims to quantify the radioactive recovery rate, determine the primary excretion pathways, evaluate the whole blood-to-plasma radioactivity ratio, identify major metabolites, and characterize the pharmacokinetic (PK) profile of HRS-1893 and its metabolites. Safety and tolerability will be monitored throughout the trial.",[95],"Cardiomyopathies","NOT_YET_RECRUITING",{"date":98,"type":34},"2026-06-18",{"date":100,"type":23},"2026-06",{"date":38,"type":23},{"name":40,"class":41},{"id":104,"slug":105,"hasResults":12,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":24,"phases":113,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100642724","phase-2-an-open-label-multicenter-phase-ii-clinical-study-to-evaluate-hrs-7058-in-patients-with-pancreatic-cancer-100642724","NCT07589569","An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer","An Open, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-7058 in Patients With Locally Advanced or Metastatic Pancreatic Cancer Harboring KRAS G12C Mutations Who Have Failed Prior Systemic Therapy.","Inclusion Criteria:\n\n1. Informed consent was obtained from all participants before participating in the study.\n2. Age from 18 to 75 years old (including both ends), regardless of gender;\n3. Patients with locally advanced unresectable, recurrent unresectable or metastatic pancreatic cancer, and adenocarcinoma confirmed by cytology or histological pathology;\n4. Participants had received at least one previous systemic therapy\n5. At least one measurable lesion according to RECIST v1.1;\n6. ECOG PS score 0 or 1;\n7. The expected survival time was more than 3 months.\n8. They were able to swallow medications and were able to adhere to trial and follow-up procedures.\n9. Adequate bone marrow and organ function within 7 days before the first dose (no use of blood components and\u002For cell growth factors within 14 days before starting study treatment;\n10. Women of childbearing potential had to agree to abstain from sexual intercourse (heterosexual intercourse) or to use a highly effective method of contraception from the time they provided informed consent until 30 days after the last dose of the trial drug. A blood test for human chorionic gonadotropin (HCG) had to be negative within 7 days before starting study treatment and she had to be nonlactating (if a serum pregnancy test was positive, pregnancy was ruled out and enrollment was confirmed after discussion with the sponsor). Men whose partner was a woman of childbearing potential had to agree to abstain from sex or to use a highly effective method of contraception from the time they provided written informed consent until 30 days after the last dose of the trial drug. Male patients also had to agree not to donate sperm during the same period\n\nExclusion Criteria:\n\n1. Presence of untreated or active central nervous system (CNS) metastases. Participants with a history of leptomeningeal metastasis or current leptomeningeal metastasis, brainstem metastasis, spinal cord metastasis, and\u002For spinal cord compression.\n2. Subjects who had received general anesthesia\n3. Subjects with a history of myocardial infarction or unstable angina pectoris\n4. Subjects with atrioventricular block or cardiac insufficiency\n5. Subjects with a history of ischemic stroke or transient ischemic attack\n6. Subjects with poor blood pressure control after medication\n7. Subjects with abnormal clotting function\n8. Subjects with a history of mental illness and a history of cognitive impairment epilepsy\n9. Subjects with a history or possibility of a difficult airway\n10. Subject with a history of substance abuse and drug abuse\n11. Adrenoceptor agonists or antagonists were used before randomization\n12. Abnormal values in the laboratory\n13. Thyroid dysfunction\n14. Allergic to a drug ingredient or component\n15. Pregnant or nursing women\n16. No birth control during the specified period of time\n17. Participated in clinical trials of other drugs (received experimental drugs)\n18. The inestigators determined that other conditions were inappropriate for participation in this clinical trial","75 Years",{"count":112,"type":23},92,[114],"PHASE2","This is a multicenter, open-label, single-arm, phase II cilinical trial designed to evaluate the efficacy and safety of the KRAS G12C selective inhibitor HRS-7058 in patients with KRAS G12C-mutated advanced pancreatic cancer who had failed 1-2 lines of previous systemic therapy.",[117],"Pancreatic Cancer","2026-06-09",{"date":120,"type":34},"2026-06-11",{"date":122,"type":34},"2026-06-04",{"date":124,"type":23},"2028-12",{"name":40,"class":41},2,{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":89,"enrollmentInfo":134,"targetDuration":4,"studyType":24,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":144,"leadSponsor":145,"locationsCount":42},"100643340","phase-1-a-clinical-study-comparing-the-bioavailability-of-hrs-2189-tablets-100643340","NCT07639905","A Clinical Study Comparing the Bioavailability of HRS-2189 Tablets","A Single-center, Single-dose, Randomized, Open-label, Two-period, Crossover Clinical Study on the Bioavailability and Safety of the New and Old Formulations HRS-2189 Tablets in Healthy Subjects","Inclusion Criteria:\n\n1. Before the trial, sign the informed consent form, fully understand the trial content, process and possible adverse reactions, and be able to complete the research in accordance with the trial protocol requirements.\n2. Participants signed the informed consent form. Their age on the day of the event was between 18 and 45 years old (inclusive of both ends).\n3. Female weight ≥ 45 kg, male weight ≥ 50 kg, and body mass index (BMI) within the range of 19.0 to 26.0 kg\u002Fm2 \\[BMI = weight (kg) \u002F height2 (m2)\\] (including both endpoints).\n4. Female participants with reproductive capacity must agree to practice contraception and avoid egg donation from the moment they sign the informed consent form until 3 months after the last administration of the investigational drug. Blood serum pregnancy tests must be negative before and during the trial, and they must not be in the lactation period. Male participants whose partners have reproductive capacity must agree to practice contraception and avoid sperm donation from the moment they sign the informed consent form until 3 months after the last administration of the investigational drug.\n\nExclusion Criteria:\n\n1. Those who have had or currently have any clinical history of serious diseases in the circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatry, and metabolism, or any chronic diseases or other diseases that may interfere with the test results.\n2. Those who have undergone major surgical procedures within one year prior to signing the informed consent form, or who have undergone any surgery within one month prior to signing the informed consent form, or who plan to undergo surgery during the trial period.\n3. Has a history of drug allergy, or is known to be allergic to the study drug\u002Frelated drugs or excipients.\n4. Those who have a history of drug use or substance abuse, or who have a positive result in drug screening tests.\n5. Those who participated in other clinical trials and took the study drug within 3 months prior to the first administration of the drug.\n6. Those who smoked at least 5 cigarettes per day for the three months prior to the trial, or those who were unable to stop using any tobacco products during the trial, or those with a positive urine nicotine screening result.\n7. Those who frequently consumed alcohol within the six months prior to the trial, namely those who drank ≥ 14 units of alcohol per week (1 unit = 360 mL of beer, or 45 mL of 40% alcohol spirits, or 150 mL of wine), or those who were unable to give up drinking during the trial, or those with a positive blood alcohol test result.\n8. The results of physical examination, vital signs, blood routine, urine routine, blood biochemistry, coagulation function, 12-lead electrocardiogram, imaging and ultrasound tests during the screening period were abnormal and had clinical significance. Based on the judgment of the researchers, they were not suitable to participate in this study.\n9. Those who are positive for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody, and HIV antibody.\n10. Pregnant and lactating women.\n11. Those with a history of fainting during blood collection or blood transfusion, or who have difficulty in blood collection or cannot tolerate venipuncture for blood collection.\n12. Due to other reasons, after the researchers' evaluation, participants who were deemed unsuitable to participate in this study were excluded.",{"count":135,"type":23},28,[26],"This study is a single-center, single-dose, randomized, open-label, two-period, crossover phase I clinical trial, comparing the bioavailability and safety of the new and old processes of HRS-2189 tablets in healthy subjects.",[139],"Malignant Solid Tumor","2026-06-05",{"date":142,"type":34},"2026-06-10",{"date":100,"type":23},{"date":38,"type":23},{"name":40,"class":41},{"id":147,"slug":148,"hasResults":12,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":153,"enrollmentInfo":154,"targetDuration":4,"studyType":24,"phases":156,"briefSummary":158,"conditions":159,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":126},"100633541","phase-3-phase-iii-study-of-hrs-7535-for-hypertension-with-overweight-or-obesity-100633541","NCT07528027","Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS-7535 for the Treatment of Hypertension in Participants With Obesity or Overweight","Inclusion Criteria:\n\n1. On the day of signing the informed consent form, the age should be between 18 and 70 years old, with no gender restrictions;\n2. When screening or randomizing, the average office blood pressure meets any of the following conditions: ① 140 mmHg ≤ SBP \\\u003C 170 mmHg, and DBP \\\u003C 110 mmHg; ② 90 mmHg ≤ DBP \\\u003C 110 mmHg, and 130 mmHg ≤ SBP \\\u003C 170 mmHg;\n3. Patients with untreated hypertension, or those who have received stable doses of any or all of the following classes of antihypertensive medications within 30 days prior to screening: 1) angiotensin-converting enzyme inhibitors\u002Fangiotensin receptor blockers (ACEI\u002FARB), 2) thiazides and thiazide-like diuretics, 3) calcium channel blockers. Patients who are currently receiving stable doses of beta blockers (such as metoprolol or atenolol) or mineralocorticoid receptor antagonists (such as spironolactone) and intend to continue these treatments at their current doses may be included in this study;\n4. During screening, BMI should be ≥24 kg\u002Fm2;\n\nExclusion Criteria:\n\n1. Having a known secondary cause of hypertension\n2. History of previously diagnosed heart failure with reduced ejection fraction (HFrEF);\n3. Those who have undergone coronary revascularization within the previous 90 days or plan to undergo it during the trial period;\n4. Diagnosed or suspected with type 1 diabetes, special type of diabetes, or secondary diabetes (excluding gestational diabetes);\n5. History of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic\u002Frequiring treatment of gallbladder disease (excluding those who have undergone cholecystectomy but are still eligible for enrollment as determined by the investigator);","70 Years",{"count":155,"type":23},648,[157],"PHASE3","The main objective of this study is to demonstrate the superior efficacy of HRS-7535 in controlling blood pressure compared to placebo in subjects with hypertension and overweight or obesity;",[160],"Hypertension With Overweight or Obesity","2026-06-03",{"date":140,"type":34},{"date":164,"type":34},"2026-05-29",{"date":166,"type":23},"2028-01",{"name":40,"class":41},{"id":169,"slug":170,"hasResults":12,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":12,"sex":175,"minAge":19,"maxAge":110,"enrollmentInfo":176,"targetDuration":4,"studyType":24,"phases":178,"briefSummary":179,"conditions":180,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":42},"100620161","phase-3-a-study-to-evluate-efficacy-and-safety-of-hrs-8080-combined-with-dalpiciclib-in-patients-with-advanced-or-metastatic-breast-cancer-resistant-to-adjuvant-endocrine-therapy-100620161","NCT07354022","A Study to Evluate Efficacy and Safety of HRS-8080 Combined With Dalpiciclib in Patients With Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.","A Multicenter, Open-label, Randomized Controlled Phase III Clinical Study Evaluating the Efficacy and Safety of HRS-8080 Combined With Dalpiciclib Versus Fulvestrant Combined With Dalpiciclib in Patients With Locally Advanced or Metastatic Breast Cancer Resistant to Adjuvant Endocrine Therapy.","Inclusion Criteria:\n\n1. Women aged 18 - 75 years old;\n2. Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 to 1;\n3. Patients with histologically confirmed locally advanced or metastatic breast cancer;\n4. Patients with prior adjuvant endocrine resistance following curative-intent surgery;\n5. Menstrual status: postmenopausal, perimenopausal, or premenopausal;\n6. Presence of evaluable lesions;\n7. Organ function must meet required criteria.\n\nExclusion Criteria:\n\n1. Patients with rapidly progressing disease, as judged by the investigator to be unsuitable for endocrine therapy;\n2. Patients who have previously received fulvestrant or other novel SERMs (excluding tamoxifen and toremifene);\n3. Patients with uncontrolled brain metastases, carcinomatous meningitis, or spinal cord compression;\n4. Patients with a history of clinically significant cardiovascular disease;\n5. Participants who have not recovered from adverse effects caused by prior therapies;\n6. Participants with a history of another malignancy within the past 5 years or currently having another malignancy;\n7. Known hypersensitivity to HRS-8080, fulvestrant, dalpiciclib, or any of their components, etc.","FEMALE",{"count":177,"type":23},912,[157],"The study is being conducted to evaluate the efficacy and safety of HRS-8080 combined with dalpiciclib versus fulvestrant combined with dalpiciclib in patients with locally advanced\u002Fmetastatic breast cancer who had developed drug resistance to prior adjuvant endocrine therapy.",[181],"Locally Advanced or Metastatic Breast Cancer","2026-06-01",{"date":184,"type":34},"2026-06-02",{"date":186,"type":34},"2026-05-05",{"date":188,"type":23},"2031-12",{"name":40,"class":41},{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":110,"enrollmentInfo":196,"targetDuration":4,"studyType":24,"phases":198,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":42},"100610620","phase-2-a-phase-2-clinical-study-to-evaluate-the-efficacy-safety-and-pharmacokinetics-of-hrs-7085-tablets-in-patients-with-inflammatory-bowel-disease-100610620","NCT07229950","A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease","Inclusion Criteria:\n\n1. Male and female subject age ≥ 18，≤75.\n2. the body mass index (BMI= weight (kg)\u002Fheight (2 m ²)) of the subjects is ≥ 18 kg\u002Fm ².\n3. Subject has active Ulcerative Colitis with a 9-point modified Mayo score of 4-9 at baseline, with an endoscopic subscore of ≥ 2 (confirmed by central read), and rectal bleeding subscore of ≥1.\n4. Subject has at least a 90-days history of Ulcerative Colitis diagnosis at baseline.\n5. Subject is deemed by the physician as having inadequate response, loss of response or intolerance to at least one conventional treatment (oral 5-ASA, immunosuppressants or corticosteroids), or anti-TNF therapy (e.g., infliximab, adalimumab) or other biological, or JAK inhibitors treatment.\n6. Subject is capable of providing a signed and dated informed consent form indicating the subject has been informed of all pertinent aspects of the study.\n7. All women of childbearing potential and their male partners must commit to using a highly effective contraception to 3 months after last dose of study medication.\n\nExclusion Criteria:\n\n1. Subject has a diagnosis of indeterminate colitis, or clinical findings suggestive of Crohn's Disease.\n2. Subject with Ulcerative Colitis, which is confined to a proctitis (distal 15 cm or less).\n3. Treatment naïve subject diagnosed with Ulcerative Colitis.\n4. Subject is displaying clinical signs of ischemic colitis, fulminant colitis or toxic megacolon.\n5. Subject had previous surgery as a treatment for Ulcerative Colitis or likely to require surgery during the study period.\n6. Screening endoscopic examination revealed that the subjects had a history of gastrointestinal dysplasia (atypical hyperplasia)\u002Fcancer or dysplasia (atypical hyperplasia)\u002Fcancer. Except for completely resected low-grade dysplasia.\n7. Subject has evidence of pathogenic bowel infection. Subjects had Clostridium difficile or other intestinal infection within 30 days of screening endoscopy or test positive at screening for C. difficile toxin or other intestinal pathogens.\n8. Subject currently has or had:\n\n   8.1 A clinically significant infection within 1 month of baseline. 8.2 A history of more than one episode of herpes zoster, or disseminated zoster (single episode).\n\n   8.3 Any infection otherwise judged by the investigator to have the potential for exacerbation by participation in the study.\n\n   8.4Any infection requiring antimicrobial therapy within 2 weeks of screening.\n9. Subject is receiving any of the following therapies:\n\n9.1 Cyclosporine, mycophenolate, tacrolimus、JAK inhibitors within 4 weeks prior to baseline.\n\n9.2 Interferon therapy within 8 weeks prior to baseline. 9.3 Intravenous corticosteroids or rectally administered formulation of corticosteroids or 5-ASA within 2 weeks prior to baseline.",{"count":197,"type":23},48,[114],"This study is a randomized, double-blind, placebo-controlled Phase II clinical trial comprising screening period, treatment period, and follow-up period. This phase 2 study is being conducted to evaluate the efficacy, safety and pharmacokinetics of HRS-7085 in patients with moderate to severe active ulcerative colitis.",[201],"Adult Patients With Moderately to Severely Active Ulcerative Colitis","2026-05-31",{"date":184,"type":34},{"date":205,"type":34},"2025-10-17",{"date":207,"type":23},"2026-12",{"name":40,"class":41},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":24,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":225,"leadSponsor":227,"locationsCount":126},"100639964","phase-3-renal-efficacy-and-safety-of-the-novel-oral-small-molecule-glp-1ra-hrs-7535-evaluated-in-participants-with-chronic-kidney-disease-100639964","NCT07625774","Renal Efficacy and Safety of the Novel Oral Small-Molecule GLP-1RA HRS-7535 Evaluated in Participants With Chronic Kidney Disease","A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Evaluate the Efficacy and Safety of HRS-7535 in Participants With Chronic Kidney Disease","RENEW-CKD","Inclusion Criteria:\n\n1. Male or female subjects, Age ≥ 18 years at the time of signing informed consent;\n2. Clinically diagnosed with chronic kidney disease at screening;\n3. CKD treatment plan consistent with current clinical guidelines or local standard of care;\n4. eGFR ≥ 20 mL\u002Fmin\u002F1.73 m² and UACR meeting protocol-specified criteria at screening and prior to randomization;\n5. Able and willing to provide a written informed consent;\n\nExclusion Criteria:\n\n1. Uncontrolled severe hypertension prior to randomization (systolic blood pressure ≥ 180 mmHg and\u002For diastolic blood pressure ≥ 110 mmHg); or systolic blood pressure \\\u003C 90 mmHg.\n2. Body mass index (BMI) \\\u003C 20 kg\u002Fm² at screening and prior to randomization.\n3. Prior history of renal transplantation, or planned renal transplantation during the trial;\n4. History or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2).\n5. History of acute or chronic pancreatitis, pancreatic injury, acute cholecystitis, or symptomatic\u002Ftreatable gallbladder disease (excluding cholecystectomy recipients);\n6. Occurrence of acute kidney injury or receipt of dialysis treatment within 3 months prior to screening or randomization;\n7. Presence of severe gastrointestinal diseases within 3 months prior to screening or randomization, or a history of major gastrointestinal surgery affecting gastric accommodation or gastric emptying;\n8. Any condition deemed inappropriate for participation in this clinical trial by the investigator.",{"count":218,"type":23},3690,[157],"This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group and event-driven phase III clinical trial. The aim of this trial is to confirm the superiority of HRS-7535 over placebo in reducing the risks of renal outcomes and cardiovascular death among participants with chronic kidney disease (CKD) on the basis of standard of care",[222],"Chronic Kidney Disease",{"date":122,"type":34},{"date":38,"type":23},{"date":226,"type":23},"2031-07",{"name":40,"class":41},{"id":229,"slug":230,"hasResults":12,"nctId":231,"briefTitle":232,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":110,"enrollmentInfo":235,"targetDuration":4,"studyType":24,"phases":237,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":126},"100586974","phase-1-a-phase-iii-of-hrs-6719-in-patients-with-advancedmetastatic-solid-tumors-100586974","NCT06922357","A Phase I\u002FII of HRS-6719 in Patients With Advanced\u002FMetastatic Solid Tumors","A Phase I\u002FII, Open-label, Multi-centre Study Evaluating the Safety,Tolerability,Pharmacokinetic (PK), Pharmacodynamics, and Preliminary Efficacy of HRS-6719 in Patients With Advanced\u002FMetastatic Solid Tumors With MTAP Deficiency","Inclusion Criteria:\n\n1. Subjects must voluntarily participate in the study and sign an informed consent form;\n2. Aged 18-75 years, male or female eligible；\n3. ECOG performance status score of 0-1；\n4. Expected survival ≥12 weeks；\n5. Patients with histologically or cytologically confirmed advanced malignant solid tumors who meet one of the following criteria:Disease progression or intolerance after receiving adequate standard therapy; Lack of standard treatment options;Currently ineligible for standard therapy；\n6. Ability to provide sufficient fresh or archived tumor tissue specimens；\n7. Adequate function of vital organs；\n8. Effective contraception must be used during the trial. For women of childbearing potential, a negative pregnancy test within 7 days prior to the first dose is required。\n\nExclusion Criteria:\n\n1. History of other malignant tumors within the past 5 years；\n2. Received systemic anti-tumor therapy within 4 weeks prior to the first study dose.\n3. Surgical procedures requiring tracheal intubation and general anesthesia were performed within 4 weeks before the first administration, diagnostic or surface surgery was performed within 1 week before the first administration, or elective surgery was expected during the trial.\n4. The study received radical radiotherapy within 4 weeks before the first medication ; and received palliative radiotherapy within 2 weeks before the first medication.\n5. Uncontrolled pleural, pericardial, or peritoneal effusions.\n6. Severe cardiac diseases occurring within 6 months prior to the first dose.\n7. Arterial\u002Fvenous thrombosis within 6 months before the first dose.\n8. Clinically significant bleeding symptoms or predisposition within 3 months prior to the first dose.\n9. Active infection or fever of unknown origin \\> 38.5 ° C was present within 4 weeks before the first administration of the study\n10. History of immunodeficiency.\n11. Active hepatitis B or C.\n12. Diseases affecting drug absorption\u002Ftransport (e.g., malabsorption syndromes).\n13. A history of severe allergic reactions to HRS-6719 and its main components was known or suspected, or there was a history of delayed allergic reactions, eczema or asthma that could not be controlled by topical corticosteroids.\n14. Use of strong CYP3A4\u002FP-gp inhibitors\u002Finducers within 5 half-lives before the first dose.\n15. Adverse events (AEs) from prior anti-tumor therapy not resolved to CTCAE v5.0 ≤ Grade 1.\n16. Patients with interstitial pneumonia or interstitial lung disease, or previous history of interstitial pneumonia or interstitial lung disease requiring hormone therapy, or clinically significant pulmonary fibrosis, persistent pneumonia, pneumonia caused by drug or radiotherapy, congenital pneumonia, or chest CT scan found any evidence of active pneumonia.\n17. Through medical history or CT examination, it was found that there was active pulmonary tuberculosis infection within 1 year before enrollment, or more than 1 year ago, there was a history of active pulmonary tuberculosis infection but no formal treatment.\n18. Live attenuated vaccines administered within 4 weeks before the first dose or planned during the study.\n19. Other factors potentially compromising study safety or data integrity.",{"count":236,"type":23},120,[26,114],"This is a Phase I\u002FII, multicenter, open-label clinical trial with dose escalation\u002Fdose expansion\u002Fefficacy expansion phases, designed to evaluate the safety, tolerability, pharmacokinetic\u002Fpharmacodynamic (PK\u002FPD) profiles, and antitumor efficacy characteristics of HRS-6719 in patients with MTAP-deficient advanced solid tumors.",[240],"Advanced\u002FMetastatic Solid Tumors","2026-05-25",{"date":243,"type":34},"2026-05-28",{"date":245,"type":34},"2025-04-24",{"date":247,"type":23},"2027-12",{"name":40,"class":41},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":12,"sex":175,"minAge":19,"maxAge":110,"enrollmentInfo":256,"targetDuration":4,"studyType":24,"phases":258,"briefSummary":259,"conditions":260,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":126},"100619780","phase-3-a-phase-iii-trial-comparing-hrs-8080-with-standard-endocrine-therapy-in-patients-with-intermediate-or-high-risk-early-breast-cancer-100619780","NCT07349069","A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer","A Randomized, Open-Label, Phase III Trial to Compare HRS-8080 Versus Standard Endocrine Therapy in Patients With Intermediate or High Risk Early Breast Cancer Who Have Received at Least 2 Years of Standard Adjuvant Endocrine Therapy","Inclusion Criteria:\n\n1. Female patients aged ≥ 18 and ≤ 75 years. Premenopausal patients must meet the eligibility of LHRH agonist therapy during the study period.\n2. Histologically confirmed invasive breast cancer by postoperative pathology, having received at least 2 years, but no more than 5 years, of adjuvant endocrine therapy.\n3. No evidence of recurrent or metastatic disease after surgery.\n4. ECOG performance status of 0 or 1.\n5. Adequate organ and bone marrow function.\n6. Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to randomization and be willing to use acceptable non-hormonal contraception methods from the time of informed consent until 7 months after the last dose of the study drug.\n7. Any acute toxicities from previous anti-tumor therapy have resolved to Grade 0-1 (per CTCAE v5.0).\n8. The patient has provided written informed consent (ICF), and is willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.\n\nExclusion Criteria:\n\n1. Tumor clinical stage IV (metastatic) breast cancer.\n2. History and\u002For treatment of any malignancy other than breast cancer within 5 years prior to randomization.\n3. History of severe pulmonary disease, such as interstitial lung disease.\n4. Concurrent or potential use of any anti-tumor therapy not specified in the study protocol.\n5. Major surgical procedure within 4 weeks prior to randomization.\n6. HIV infection or known AIDS, active hepatitis B, hepatitis C, or co-infection with hepatitis B and C.\n7. Poor cardiac function.\n8. Severe infection within 4 weeks prior to randomization.\n9. History of drug allergy.\n10. History of organ transplantation.\n11. History of substance abuse.\n12. Women within 1 year postpartum or who are currently breastfeeding.\n13. Patients deemed by the investigator as unsuitable for participation in this study.",{"count":257,"type":23},5500,[157],"The study is being conducted to evaluate the efficacy and safety of HRS-8080 in patients with intermediate or high risk early breast cancer.",[261],"Breast Cancer","2026-05-18",{"date":264,"type":34},"2026-05-22",{"date":266,"type":34},"2026-03-04",{"date":268,"type":23},"2034-01",{"name":40,"class":41},{"id":271,"slug":272,"hasResults":12,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":110,"enrollmentInfo":277,"targetDuration":4,"studyType":24,"phases":279,"briefSummary":280,"conditions":281,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":286,"leadSponsor":288,"locationsCount":42},"100638993","phase-3-a-trial-of-hrs-7058-in-advanced-or-metastatic-non-small-cell-lung-cancer-patients-who-have-failed-standard-treatment-100638993","NCT07601048","A Trial of HRS-7058 in Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment","A Randomized, Open-Label, Multicenter Phase III Trial of HRS-7058 Versus the Investigator-Selected KRAS G12C Inhibitor in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment","Inclusion Criteria:\n\n1. Age 18 years old to 75 years old ( including both ends ), regardless of gender ;\n2. Subjects with histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer ;\n3. Histological specimens confirmed the presence of KRAS G12 C mutation ;\n4. Participants who have failed at least one line of systemic anti-tumor treatment in the locally advanced or metastatic stage. Previous systemic anti-tumor treatment should include : platinum-containing double-agent chemotherapy and immune checkpoint inhibitor therapy ( synchronous or sequential, except that the researchers determine that it is not suitable for immune checkpoint inhibitors or chemotherapy ) ;\n5. At least one measurable lesion conforming to the definition of RECIST v1.1 standard ;\n6. ECOG physical score 0-1 points ;\n7. Expected survival time ≥ 12 weeks ;\n8. Have adequate bone marrow and organ function\n9. Subjects were required to give informed consent to this study before the trial and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Subjects with active central nervous system ( CNS ) metastasis ;\n2. Other malignant tumors occurred within 5 years before the first administration, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, ductal carcinoma in situ after radical resection, and papillary thyroid carcinoma after radical resection.\n3. Having undergone major surgery or significant trauma within 4 weeks prior to the first use of the study drug ;\n4. Subjects with a history of interstitial pneumonia or suspected interstitial pneumonia by imaging examination during screening ; or other lung diseases that seriously affect lung function ;\n5. Have serious cardiovascular and cerebrovascular diseases\n6. Severe infection occurred within 4 weeks before the first administration.\n7. The first study of arterial \u002F venous thrombosis events within 3 months before medication was conducted.\n8. Have a history of immunodeficiency, including HIV test positive ;\n9. There is active hepatitis B or hepatitis C ;\n10. Subjects with active central nervous system ( CNS ) metastasis ;",{"count":278,"type":23},450,[157],"The study is being conducted to evaluate the efficacy, and safety of HRS-7058 in KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment",[282],"KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer Patients Who Have Failed Standard Treatment","2026-05-15",{"date":264,"type":34},{"date":100,"type":23},{"date":287,"type":23},"2029-05",{"name":40,"class":41},{"id":290,"slug":291,"hasResults":12,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":296,"enrollmentInfo":297,"targetDuration":4,"studyType":24,"phases":299,"briefSummary":300,"conditions":301,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":305,"completionDateStruct":307,"leadSponsor":309,"locationsCount":42},"100617699","phase-1-a-study-of-hrs-1301-tablets-in-healthy-subjects-and-those-with-impaired-kidney-function-100617699","NCT07322016","A Study of HRS-1301 Tablets in Healthy Subjects and Those With Impaired Kidney Function","A Single-dose, Open-label Phase I Clinical Trial Comparing the Pharmacokinetics, Safety and Pharmacodynamics of HRS-1301 Tablets in Subjects With Mild, Moderate and Severe Renal Insufficiency and Healthy Subjects","Inclusion Criteria:\n\n1. Sign the informed consent before the trial, and fully understand the content, process, and possible adverse reactions of the trial;\n2. Male or female subjects aged 18 to 65 (including 18 and 65);\n3. Body mass index (BMI) ranges from 18 kg\u002Fm2 to 30 kg\u002Fm2 (including 18 and 30),and Male weight ≥ 50.0 kg, female weight ≥ 45.0 kg;\n4. The glomerular filtration rate should meet the following criteria (GFR, mL\u002Fmin): Subjects with mild renal impairment: 60-89 mL\u002Fmin; Subjects with moderate renal impairment: 30-59 mL\u002Fmin; Subjects with severe renal function impairment: 15\\~29 mL\u002Fmin.\n\nExclusion Criteria:\n\n1. Individuals with a specific history of allergies (such as asthma, urticaria, eczema, etc.), or those with an allergic constitution (such as those allergic to any drug or food), or those known to be allergic to any component of the studied drug;\n2. Those with cardiogenic shock, severe conduction obstruction, sick sinus syndrome, heart failure (NYHA grade III-IV), persistent rapid arrhythmia, tortuous ventricular tachycardia or ventricular tachycardia at the pointed point, a history of clinically significant T-wave changes, myocardial infarction, or angina pectoris;\n3. Suffering from malignant tumors, or having a history of malignant tumors within 5 years prior to screening (excluding skin non-melanomas that have been treated without recurrence signs and resected cervical intraepithelial neoplasia);\n4. Those with a history of gastric or intestinal surgery that some researchers believe may affect drug absorption;\n5. Those who have suffered severe trauma or undergone major surgical operations within the three months prior to screening, or who plan to undergo surgery during the trial period;\n6. Those who have participated in any clinical trials of drugs or medical devices within three months prior to screening, or those who are still within five half-lives of the drug before screening (whichever is longer);\n7. Those who have donated blood of ≥ 400 mL within 4 weeks before screening, or have suffered severe blood loss (blood loss ≥ 400 mL), or have received blood transfusion within 8 weeks;\n8. Those who received live (attenuated) vaccines within 4 weeks prior to screening or those who plan to receive them during the trial;\n9. Those with potential difficulties in blood collection and a history of fainting at the sight of needles or blood;\n10. For patients with renal insufficiency,those who have received renal replacement therapy (such as peritoneal dialysis, hemodialysis, etc.) within 3 months prior to the screening or during the expected trial period;\n11. For patients with renal insufficiency，screening individuals with underlying diseases that induce chronic kidney disease within the previous three months and are judged by researchers to be poorly controlled, such as diabetic patients with HbA1c \\> 10%, and hypertensive patients with systolic blood pressure \\> 180 mmHg and diastolic blood pressure \\> 120 mmHg, etc.","65 Years",{"count":298,"type":23},36,[26],"The primary objective of this study is to evaluate pharmacokinetics of HRS-1301 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal impairment.",[73],"2026-05-08",{"date":304,"type":34},"2026-05-13",{"date":306,"type":34},"2026-01-13",{"date":308,"type":23},"2026-10",{"name":40,"class":41},{"id":311,"slug":312,"hasResults":12,"nctId":313,"briefTitle":314,"officialTitle":315,"acronym":4,"eligibilityCriteria":316,"healthyVolunteers":12,"sex":18,"minAge":317,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":24,"phases":319,"briefSummary":320,"conditions":321,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":42},"100613678","phase-2-a-phase-ii-clinical-trial-of-hrs-1893-in-the-treatment-of-heart-failure-with-preserved-ejection-fraction-100613678","NCT07269717","A Phase II Clinical Trial of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial on the Efficacy and Safety of HRS-1893 in the Treatment of Heart Failure With Preserved Ejection Fraction","Inclusion Criteria:\n\n1. Age ≥ 40 years at screening, regardless of gender;\n2. Body mass index \\\u003C 35 kg\u002Fm²;\n3. Diagnosed with chronic heart failure before screening, and meeting relevant diagnostic criteria during the screening period: (1) Transthoracic echocardiography (TTE) at screening showing a resting left ventricular ejection fraction (LVEF) ≥ 60%; (2) Elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) during the screening period; (3) Echocardiography showing structural or functional abnormalities of the heart, etc.;\n4. New York Heart Association (NYHA) classification of II or III at screening;\n5. KCCQ-CSS score between ≥25 and ≤75 at screening;\n6. Resting oxygen saturation \\>90% without supplemental oxygen at screening;\n7. Female participants of childbearing potential must have a negative serum pregnancy test before the first dose and must not be breastfeeding during the study. Female participants of childbearing potential and male participants whose partners are women of childbearing potential must agree to avoid donating sperm\u002Feggs from the time of signing the informed consent until three months after the last dose of the study drug and comply with relevant contraceptive requirements;\n8. Understand the study procedures and methods, voluntarily participate in this trial, and provide written informed consent.\n\nExclusion Criteria:\n\n1. Previously diagnosed or found during screening with hypertrophic cardiomyopathy (HCM), or having infiltrative\u002Fgenetic\u002Fstorage diseases that cause heart failure with preserved ejection fraction (HFpEF)\u002Fmyocardial hypertrophy (such as amyloidosis, Fabry disease, Noonan syndrome with left ventricular hypertrophy), or complete M protein or monoclonal light chain (such as κ or λ) detected in serum protein electrophoresis and serum immunofixation electrophoresis during screening (researchers may deem not applicable if amyloidosis\u002Fmultiple myeloma are excluded);\n2. Previously diagnosed or found during screening with hyperthyroidism;\n3. At any time in their clinical history, previously experienced left ventricular systolic dysfunction (LVEF \\\u003C45%);\n4. History of syncope or sustained ventricular tachycardia within 6 months prior to screening;\n5. Previously experienced cardiac arrest with resuscitation at any time or received ICD therapy for life-threatening ventricular arrhythmia within 6 months prior to screening;\n6. Previously diagnosed or found during screening with atrial fibrillation;\n7. Coronary artery disease (stenosis \\>70% in one or more coronary arteries) or myocardial infarction: newly developed within 6 months prior to screening, or occurred more than 6 months prior without completed revascularization (such as percutaneous coronary intervention or coronary artery bypass grafting);\n8. Moderate to severe aortic stenosis, hemodynamically significant mitral stenosis, or severe mitral\u002Ftricuspid regurgitation at screening (as determined by the investigator);\n9. Severe chronic obstructive pulmonary disease (COPD) or other pulmonary diseases requiring home oxygen therapy, chronic nebulization\u002Foral steroid treatment, or hospitalization due to pulmonary decompensation in the past 12 months;\n10. Acute respiratory infection at screening;\n11. Required intravenous diuretics, inotropes, vasodilators, or left ventricular assist device therapy for acute decompensated heart failure within 30 days prior to screening;\n12. Clinically significant history of malignancy within the past 5 years (excluding cancers that have been confirmed cured or in remission for ≥5 years, basal or squamous cell skin cancer that was radically excised within 5 years, carcinoma in situ of the cervix, and excised colon polyps);\n13. Electrocardiogram abnormalities posing safety risks at screening (as determined by the investigator, such as second-degree type II AV block, complete AV block, symptomatic ventricular arrhythmias, torsades de pointes, etc.);\n14. Any clinically significant abnormal screening laboratory values during screening deemed unsuitable for enrollment by the investigator;\n15. Positive result in any infectious disease screening during screening, including hepatitis B surface antigen, hepatitis C antibody, syphilis antibody, HIV antibody (or AIDS virus antibody or P24 antigen);\n16. Inability to complete the six-minute walk test during screening (e.g., due to leg fractures, post-stroke mobility impairment);\n17. Patients who received β-blockers, diltiazem, or verapamil prior to screening but were not on a stable dose for more than 4 weeks before randomization, or are expected not to maintain the same medication regimen during the trial;\n18. Subjects who received heart failure medication treatment (diuretics, sodium-glucose co-transporter 2 inhibitors \\[SGLT2i\\], angiotensin receptor-neprilysin inhibitors \\[ARNI\\], mineralocorticoid receptor antagonists \\[MRA\\], angiotensin-converting enzyme inhibitors \\[ACEI\\], angiotensin II receptor blockers \\[ARB\\], glucagon-like peptide-1 \\[GLP-1\\] or GLP-1\u002Fglucose-dependent insulinotropic polypeptide \\[GIP\\]) prior to screening but have not been on a stable dose for more than 4 weeks before randomization, or are expected to be unable to maintain the same medication regimen during the trial;\n19. Subjects who used a myosin inhibitor within a period shorter than 5 half-lives before the trial drug administration;\n20. Subjects who participated in any drug or medical device clinical trial within 3 months prior to screening (participation in a clinical trial is defined as the subject having received the trial drug or medical device treatment);\n21. Other conditions deemed by the investigator that make the subject unsuitable for participation in the trial, such as conditions that may increase trial risk, affect the subject's protocol compliance, or impact the subject's ability to complete the trial due to physiological or psychological diseases or conditions.","40 Years",{"count":197,"type":23},[114],"This study aims to evaluate the safety and tolerability of HRS-1893 in subjects with heart failure with preserved ejection fraction.",[322],"Heart Failure With Preserved Ejection Fraction",{"date":324,"type":34},"2026-05-11",{"date":326,"type":34},"2026-03-30",{"date":328,"type":23},"2027-05",{"name":40,"class":41},{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":4,"eligibilityCriteria":336,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":337,"targetDuration":4,"studyType":24,"phases":339,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":126},"100629154","phase-2-a-phase-ii-clinical-study-on-the-efficacy-and-safety-of-hrs-1780-in-participants-with-primary-aldosteronism-100629154","NCT07470983","A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism","A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism","Inclusion Criteria:\n\n1. Male or female, aged ≥ 18 years on the date of signing the informed consent form.\n2. Diagnosed with primary aldosteronism.\n3. No use of antihypertensive drugs before screening, or stable use of antihypertensive drugs.\n4. Voluntarily sign the informed consent form before the trial, fully understand the trial content, procedures, and possible adverse reactions, and be capable and willing to comply with the protocol requirements to complete the study.\n5. From the signing of the informed consent form until 4 weeks after the last dose, the participant has no plan for procreation and is willing to adopt the highly effective contraceptive measures specified in the protocol.\n\nExclusion Criteria:\n\n1. Has known secondary causes of hypertension.\n2. Has previously undergone, or plans to undergo during the study period, adrenal-related surgeries, including adrenalectomy, adrenal ablation, etc.\n3. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m².\n4. Has had any malignancy of an organ system within 5 years before screening.\n5. Has received any other investigational drug within 90 days or 5 half-lives before screening (whichever is longer).\n6. Has a history of blood donation or blood loss ≥ 400 mL within 3 months before screening, or has received a blood transfusion within 2 months.\n7. Known or suspected alcohol or narcotic abuse.\n8. Women who are pregnant, breastfeeding, planning pregnancy, or of childbearing potential unable to adopt highly effective contraceptive measures; or men unable to adopt highly effective contraceptive measures.\n9. Abnormal daily routine.\n10. Use of strong inhibitors\u002Finducers of cytochrome P450 3A4 (CYP3A4) within 1 week before randomization.\n11. Severe infection, severe trauma, or major or medium-scale surgery within 1 month prior to screening;\n12. Stroke, transient ischemic attack, myocardial infarction, symptomatic heart failure (NYHA III-IV), or coronary revascularization within 3 months prior to screening; and\u002For planned coronary, carotid, or peripheral artery revascularization at the time of screening;\n13. Within 6 months prior to the screening period, participants have clinically significant diseases that, in the judgment of the investigator, may interfere with the trial results or pose additional risks to the administration of the study drug, including but not limited to respiratory, digestive, cardiovascular, endocrine, immune, urinary, adrenal (except for the primary disease), hematological, neurological, psychiatric, or other conditions;\n14. Presence or suspected presence of depression, bipolar disorder, suicidal tendencies, schizophrenia, or other severe mental disorders; or participants with mental incapacity or language barriers that prevent them from adequately understanding or participating in the trial process;\n15. Alanine aminotransferase (ALT) ≥ 3 × upper limit of normal (ULN);\n16. Aspartate aminotransferase (AST) ≥ 3 × ULN;\n17. In the judgment of the investigator, any condition that may affect participant safety or otherwise interfere with the evaluation of trial results (including medical, psychological, social, or geographical factors).",{"count":338,"type":23},60,[114],"This study is a multicenter, randomized, double-blind, placebo-parallel-controlled phase II clinical trial to evaluate the efficacy and safety of HRS-1780 compared with placebo in participants with primary aldosteronism. The study plans to enroll 60 participants.",[342],"Primary Aldosteronism","2026-04-29",{"date":345,"type":34},"2026-04-30",{"date":347,"type":34},"2026-04-23",{"date":349,"type":23},"2026-11",{"name":40,"class":41},{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":17,"sex":88,"minAge":19,"maxAge":89,"enrollmentInfo":358,"targetDuration":4,"studyType":24,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":368,"locationsCount":42},"100635801","phase-1-a-mass-balance-study-of-14chrs-1780-in-healthy-adult-male-subjects-100635801","NCT07557407","A Mass Balance Study of [14C]HRS-1780 in Healthy Adult Male Subjects","An Open-label, Mass Balance Study to Investigate the Absorption, Metabolism and Excretion of [14C]HRS-1780 After a Single Oral Dose to Healthy Male Subjects","Inclusion Criteria:\n\n1. Before the trial, sign the informed consent form, fully understand the trial content, process and possible adverse reactions, and be willing to complete the research as required by the trial protocol.\n2. Aged 18 to 45 years old (inclusive) who are in good health and have signed the informed consent form on that day.\n3. Body weight of no less than 50 kg and a body mass index (BMI) within the range of 19.0 to 26.0 kg\u002Fm2 (inclusive).\n4. Participants (including their partners) shall have no intention to have children or donate sperm within three months after signing the informed consent form and shall voluntarily adopt the contraceptive measures stipulated in the protocol.\n\nExclusion Criteria:\n\n1. Clinically significant abnormalities in vital signs (complete physical examination, laboratory tests, biochemistry, urinalysis, coagulation function, stool routine and occult blood, thyroid function), 12-lead electrocardiogram, digital rectal examination, chest X-rays, abdominal ultrasound.\n2. Positive hepatitis B virus (HBsAg), hepatitis B core antibody (HbcAb), hepatitis C virus (HCV Ab), human immunodeficiency virus (HIV), or syphilis at screening.\n3. Receipt of medical devices or another investigational drug (including placebo) within the previous 3 months or within the 5 half-lives (whichever is longer), and plan to participate in other clinical trials of drugs or medical devices during the trial period.\n4. History of illicit or prescription drug abuse in the past five years or drug addiction within 3 months of screening, or positive urine drug screen at screening\u002Fbaseline.\n5. Use of any prescription medicine within 2 weeks, or over-the-counter (OTC) medicine, herbal remedy, or nutritional supplement, or within 5 half-lives of any drugs, whichever is longer prior to dosing, except for vitamins and occasional use of paracetamol (≤ 2 g\u002Fday; no more than 3 consecutive days).\n6. History or evidence of clinically significant disorders (including but not limited to immunologic, hepatic, renal, digestive, urinary, psychiatric, respiratory, hematologic, endocrine, or metabolic disorders) and deemed not suitable to participate in the study by the investigator.\n7. Severe systemic infections, injuries, or major surgeries as determined by the investigator within 3 months prior to screening, or plan to do surgeries during the study.\n8. Whole blood\u002Fplasma donation or loss ≥ 200 mL of blood within 3 months prior to dosing; received a blood\u002Fplasma transfusion.\n9. Alcohol abuse or consumption of more than 14 units of alcohol per week within the previous 6 months (1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); or those who have taken alcohol-containing products within 48 hours before administration; or those with a positive alcohol breath test at baseline; or those who were unable to abstain from alcohol during the trial.\n10. History of excessive smoking in the past 1 month prior to screening which is defined as more than 5 cigarettes daily (or products with an equivalent amount of nicotine); or positive cotinine test at baseline, or unable to abstain from smoking within 48 h prior to D-1\u002Fcheck-in and during the trial.\n11. Receipt of a vaccine within 2 weeks prior to administration or are scheduled to receive a vaccine during the study period and within 1 month after administration.\n12. Any other circumstances (e.g., not suitable for venous access) or laboratory abnormality that, in the investigator's judgment, may increase the risk to the participant, or be associated with the participant's participation in and completion of the study or could preclude the evaluation of the participant's response.",{"count":91,"type":23},[26],"The study aims to evaluate the pharmacokinetics, mass balance recovery, metabolite profile and metabolite identification of \\[14C\\]HRS-1780 following an oral single dose in healthy adult male participants.",[362],"Chronic Kidney Diseases","2026-04-22",{"date":343,"type":34},{"date":366,"type":23},"2026-05",{"date":100,"type":23},{"name":40,"class":41},{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":24,"phases":378,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":387,"locationsCount":126},"100621984","phase-1-a-study-of-hrs-2129-in-patients-with-diabetic-peripheral-neuropathic-pain-100621984","NCT07377721","A Study of HRS-2129 in Patients With Diabetic Peripheral Neuropathic Pain","A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo and Pregabalin Capsule Controlled, Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Chinese Patients With Diabetic Peripheral Neuropathic Pain","Inclusion Criteria:\n\n1. Able and willing to provide a written informed consent.\n2. Males or females aged ≥18years of age inclusive.\n3. Diagnosis of diabetic peripheral neuropathic pain (DPNP) and diabetic peripheral neuropathy (DPN) pain ≥ 3 months.\n4. HbA1c ≤ 9.0% at screening and on a stable antidiabetic medication regimen for at least 30 days prior to screening as far as possible.\n5. At Screening, pain scale (Visual Analog Scale, VAS) of ≥ 40 mm and \\\u003C 90 mm.\n\nExclusion Criteria:\n\n1. Subjects with a history of severe allergies.\n2. Peripheral neuropathy or pain unrelated to diabetic peripheral neuropathy (DPN) that may confuse the assessment of diabetic peripheral neuropathic pain (DPNP).\n3. Subjects with abnormal liver and renal function.\n4. Corrected QT Interval (QTc): \\> 450 ms (male), \\> 470 ms (female).\n5. Failure to response to previous treatment with pregabalin at doses ≥ 300 mg\u002Fd or gabapentin at doses ≥ 1200 mg\u002Fd for treatment of diabetic peripheral neuropathic pain (DPNP).\n6. History of suicidal behavior or attempted suicide.\n7. Participated in another clinical study within 3 months prior to screening.",{"count":377,"type":23},168,[26],"This study aims to investigate the efficacy and safety of HRS-2129 in Chinese diabetic peripheral neuropathic pain (DPNP) in comparison to placebo.",[381],"Diabetic Peripheral Neuropathic Pain",{"date":383,"type":34},"2026-04-15",{"date":385,"type":34},"2026-03-24",{"date":349,"type":23},{"name":40,"class":41},{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":175,"minAge":19,"maxAge":110,"enrollmentInfo":395,"targetDuration":4,"studyType":24,"phases":397,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":401,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":406,"locationsCount":126},"100622908","phase-1-a-study-of-hrs-6208-in-combination-with-hrs-8080-or-fulvestrant-or-letrozole-with-or-without-hrs-6209-in-patients-with-advanced-unresectable-or-metastatic-breast-cancer-100622908","NCT07389733","A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer","Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HRS-6208 in Combination With HRS-8080 ± HRS-6209, or in Combination With Fulvestrant ± HRS-6209, or in Combination With Letrozole ± HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer: an Open Label, Multicenter, Phase Ib\u002FII Study","Inclusion Criteria:\n\n1. Female, aged 18-75 (inclusive);\n2. ECOG score 0-1;\n3. Estimated survival time ≥ 12 weeks;\n4. Possessing adequate bone marrow and organ function;\n5. Participants of reproductive\u002Fchildbearing potential must agree to take adequate and effective contraceptive measures from the time they sign the informed consent form, during the study treatment period, and up to 2 years after the last use of the trial medication;\n6. Participants must provide informed consent for this study before the trial and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Within 5 years prior to the first dose of study medication, the occurrence of other malignancies, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, and post-radical surgery thyroid papillary carcinoma;\n2. Active brain metastasis, carcinomatous meningitis, spinal cord compression, or history of primary central nervous system tumors;\n3. Severe bone damage caused by tumor bone metastasis as determined by the investigator;\n4. Adverse events caused by previous anti-tumor treatment have not been resolved;\n5. Participants with one of multiple factors affecting oral medication;\n6. History of severe cardiovascular and cerebrovascular diseases;\n7. Presence of severe infections;\n8. Significant clinically meaningful bleeding within 3 months prior to the first dose of study medication;\n9. Active autoimmune diseases, history of immune deficiency, history of autoimmune diseases, or history of diseases or syndromes requiring systemic steroid hormone or immunosuppressive drug treatment, or acquired conditions (HIV infection), congenital immune deficiency diseases, or history of organ transplantation;\n10. Active untreated hepatitis;\n11. History of active tuberculosis infection within 1 year prior to enrollment, or history of active tuberculosis infection more than 1 year ago without standard treatment;\n12. Washout period of prior drug or treatment did not meet protocol requirements before the first dose of study medication;\n13. Prior use of prohibited drugs specified in the protocol;\n14. Is pregnant or breastfeeding or planning to become pregnant within 2 years after the last dose of study medication;\n15. History of clear neurological or psychiatric disorders, and participants with a history of psychiatric drug abuse or drug addiction;\n16. Allergic reactions to any study drug or excipients;\n17. Factors confirmed by the investigator as unsuitable for participation in this clinical study.",{"count":396,"type":23},180,[26,114],"This study aims to evaluate the safety, tolerability, efficacy and pharmacokinetics of HRS-6208 in combination with HRS-8080 ± HRS-6209, or in combination with fulvestrant ± HRS-6209, or in combination with letrozole ± HRS-6209 in patients with advanced unresectable or metastatic breast cancer.",[400],"Advanced Unresectable or Metastatic Breast Cancer of Adults",{"date":402,"type":34},"2026-04-03",{"date":404,"type":34},"2026-03-27",{"date":124,"type":23},{"name":40,"class":41},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":414,"enrollmentInfo":415,"targetDuration":4,"studyType":24,"phases":417,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":421,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":426,"locationsCount":42},"100625222","phase-3-a-phase-iii-clinical-study-on-the-efficacy-and-safety-of-hrs-1780-in-the-treatment-of-patients-with-chronic-kidney-disease-100625222","NCT07419828","A Phase III Clinical Study on the Efficacy and Safety of HRS-1780 in the Treatment of Patients With Chronic Kidney Disease","A Multicenter, Randomized, Double-blind, Placebo- Controlled Phase III Study Evaluating the Efficacy and Safety of HRS-1780 in Adult Participants With Chronic Kidney Disease","Inclusion Criteria:\n\n* Male or female, aged ≥18 and \\\u003C80 years old on the day of signing the informed consent form;\n* a) The estimated glomerular filtration rate calculated by the CKD-EPI 2009 formula of the Chronic Kidney Disease Epidemiology Collaboration was eGFR≥25 and \\\u003C90 mL\u002Fmin\u002F1.73 m2, and UACR≥500 mg\u002Fg and ≤5000 mg\u002Fg; Or b) eGFR≥25 and \\\u003C60 mL\u002Fmin\u002F1.73 m2, and UACR≥200 mg\u002Fg and \\\u003C500 mg\u002Fg;\n* Serum potassium ≤4.8 mmol\u002FL\n* HbA1c was less than 10.5%.\n\nExclusion Criteria:\n\n* Uncontrolled severe hypertension at the time of screening or randomization (systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg), or systolic blood pressure \\\u003C90 mmHg;\n* Alanine aminotransferase (ALT) \\>3× upper limit of normal (ULN); Aspartate aminotransferase (AST) \\>3×ULN; Total bilirubin \\>2.0×ULN;\n* Diagnosis or suspicion of polycystic kidney disease, anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis;\n* Acute kidney injury occurred within 90 days before screening or hemodialysis or peritoneal dialysis treatment was received;\n* Have received a kidney transplant in the past or plan to receive a kidney transplant during the trial period;\n* There are diseases that may cause hyperkalemia during screening or randomization (such as Addison's disease);\n* Within 180 days prior to the screening, the participants had the following diseases of clinical significance, which, as determined by the investigators, might interfere with the trial results or pose additional risks to the administration of the study drug: including but not limited to respiratory system, digestive system, cardiovascular and cerebrovascular, endocrine, immune, urinary, adrenal, blood, nervous, mental and other diseases;\n* Stroke, transient ischemic attack, myocardial infarction, coronary revascularization, and decompensated heart failure (NYHA grade III-IV) occurred within 90 days before screening. And\u002For planned to undergo coronary, carotid or peripheral artery revascularization at the time of screening","80 Years",{"count":416,"type":23},1978,[157],"The study is a Phase III clinical trial to evaluate the superiority of HRS-1780 tablets compared with placebo in delaying renal function decline in participants with chronic kidney disease (CKD) on the basis of standard treatment.",[222],"2026-03-25",{"date":404,"type":34},{"date":423,"type":34},"2026-03-13",{"date":425,"type":23},"2030-05",{"name":40,"class":41},{"id":428,"slug":429,"hasResults":12,"nctId":430,"briefTitle":431,"officialTitle":432,"acronym":4,"eligibilityCriteria":433,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":24,"phases":436,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":420,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":444,"locationsCount":91},"100575306","phase-1-a-clinical-study-to-evaluate-the-safety-tolerability-and-pharmacokinetics-of-hrs-3802-monotherapy-in-patients-with-malignant-solid-tumors-100575306","NCT06770569","A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors","A Single-arm, Open-Label, Multi-center Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors","Inclusion Criteria:\n\n1. Patients must be willing to participate in the study, sign the informed consent form, have good compliance, and cooperate with follow-up visits;\n2. Age ≥18 years, male or female;\n3. Patients with advanced malignant tumors confirmed pathologically;\n4. Failure of adequate standard treatment, or no effective standard treatment;\n5. Patients must have at least 1 extracranial measurable target lesion per RECIST v1.1;\n6. The expected survival period is more than 12 weeks;\n7. The Eastern Cooperative Oncology Group (ECOG) physical fitness score is 0 - 1;\n8. Have sufficient bone marrow and organ function (have not received blood transfusion or hematopoietic stimulating factor treatment within 14 days);\n9. Female subjects of childbearing age must undergo a serum pregnancy test within 7 days before starting the study medication, and the result is negative, and are willing to use a medically approved high-efficiency contraception during the study period and within 1 months after the last administration of the study drug Measures.\n\nExclusion Criteria:\n\n1. Subjects had cancerous meningitis or untreated central nervous system metastases;\n2. Subjects had severe cardiovascular and cerebrovascular diseases;\n3. There is third-space effusion that cannot be controlled by drainage and other methods (such as massive ascites, pleural effusion, pericardial effusion);\n4. Subjects had or currently had idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia , drug pneumonia, or CT during screening showed active pneumonia;\n5. Arteriovenous thrombosis occurred within 6 months prior to the first dose;\n6. Severe infection occurred within 4 weeks prior to initial administration;\n7. Subjects with refractory nausea, vomiting, or other gastrointestinal disorders that affect the use of oral medications: including malabsorption syndrome;\n8. Known history of human immunodeficiency virus (HIV) seropositive status or acquired immunodeficiency syndrome (AIDS);\n9. Subjects had active hepatitis;\n10. Subjects were scheduled to receive other systemic antitumor therapies during the study period;\n11. Known allergies and contraindications to the investigational drug or any of its components;\n12. Other factors as judged by the investigator that may lead to the termination of the study, such as other serious diseases, serious laboratory test abnormalities, or family or social factors that could affect the safety of the subject, or the collection of study data and samples.",{"count":435,"type":23},100,[26],"The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-3802 monotherapy in patients with malignant solid tumors.",[439],"Advanced Solid Tumors",{"date":326,"type":34},{"date":442,"type":34},"2025-01-21",{"date":124,"type":23},{"name":40,"class":41},{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":414,"enrollmentInfo":452,"targetDuration":4,"studyType":24,"phases":454,"briefSummary":455,"conditions":456,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":460,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":465,"locationsCount":42},"100620003","phase-1-a-phase-ib-study-to-evaluate-the-efficacy-and-safety-of-hrs-2129-in-patients-with-knee-osteoarthritis-100620003","NCT07351968","A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis","A Multicenter, Randomized, Double-blind, Agent-positive and Placebo-controlled, Parallel-group Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form before starting the activities related to the trial;\n2. The Numerical Evaluation Scale (NRS) pain score of the index knee joint at screening is ≥ 4;\n3. Subjects must be willing to discontinue all medical and non-medical treatments for osteoarthritis pain except rescue medication (acetaminophen) and not use prohibited analgesics throughout the study ;\n4. Male and female subjects of childbearing potential must agree to use highly effective contraceptive measures with their partners from the signing of the informed consent form until 1 month after the last dose of investigational product.\n\nExclusion Criteria:\n\n1. History of other diseases that may involve the target joint;\n2. History of major trauma or surgery of knee joint and hip joint in the past year;\n3. Plan to undergo surgical procedure during the study;\n4. Most or complete loss of mobility;\n5. There are other diseases that may confuse the assessment of osteoarthritis pain;\n6. There is a neuropsychiatric disease, and the investigator's assessment may affect the evaluation of osteoarthritis (OA) or self-score;\n7. There are serious or poorly controlled concomitant diseases;\n8. Those who have a clear history of peptic ulcer, bleeding, perforation or obstruction within 1 year before screening, and have been clinically diagnosed;\n9. Those who require drug treatment or surgical intervention;\n10. History of malignant tumors within 5 years before screening;\n11. Have a history of drug abuse, drug abuse and\u002For alcoholism within 2 years before screening.",{"count":453,"type":23},200,[26],"Primary Objective: To explore the effectiveness of different doses of HRS-2129 in the treatment of patients with moderate to severe pain in knee osteoarthritis. Secondary Objectives: To evaluate the safety of different doses of HRS-2129 for the treatment of patients with moderate to severe pain in knee osteoarthritis; To evaluate the population pharmacokinetic profile of HRS-2129 in patients with knee osteoarthritis.",[457,458],"Moderate Pain in Knee Osteoarthritis","Severe Pain in Knee Osteoarthritis","2026-03-18",{"date":461,"type":34},"2026-03-19",{"date":463,"type":34},"2026-03-10",{"date":80,"type":23},{"name":40,"class":41},{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":110,"enrollmentInfo":473,"targetDuration":4,"studyType":24,"phases":474,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":459,"lastUpdatePostDateStruct":478,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":42},"100595409","phase-2-a-clinical-trial-of-hrs-7058-combined-anti-tumor-drugs-in-subjects-with-solid-tumors-100595409","NCT07032077","A Clinical Trial of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors","A Phase II Clinical Trial on the Safety, Tolerability, and Efficacy of HRS-7058 Combined Anti-tumor Drugs in Subjects With Solid Tumors","Inclusion Criteria:\n\n1. Patients who are capable of giving informed consent, have signed the informed consent form approved by the IRB\u002FEC and noted the date, and are willing and able to comply with the treatment plan, visits, various examinations, and other procedural requirements.\n2. Age must be between 18 and 75 years old (inclusive) when signing the informed consent form, gender is unrestricted.\n3. ECOG score of 0 or 1.\n4. Expected survival period ≥ 12 weeks.\n5. Provide 5-15 pieces of tumor tissue blocks fixed in formalin and embedded in paraffin, or unstained tumor specimen slices. The samples should be archived within the first 3 years before treatment or freshly obtained (freshly obtained is preferred). Slices do not need to be provided during the dose escalation phase.\n6. According to the RECIST v1.1 standard, there must be at least one measurable lesion.\n7. The functions of important organs meet the standards (no blood components or cell growth factors were used for corrective treatment within 14 days prior to the first administration of the drug), and the examination results must be completed within 7 days before the first study treatment.\n8. Female subjects of childbearing potential must undergo a serum pregnancy test within 7 days prior to the first dose, and the result must be negative (if the serum HCG test is positive, pregnancy causes must be ruled out and further discussion with the sponsor is required); and must not be breastfeeding. Female subjects of childbearing potential and male partners of female subjects of childbearing potential must agree to follow contraceptive requirements from the time of signing the informed consent until 5 months after the last administration of the study drug (for male subjects) or 8 months (for female subjects) (see \"Methods of Contraception\" in the study protocol attachments for details).\n\nExclusion Criteria:\n\n1. Subjects with untreated or active CNS metastases, a history of meningeal metastasis, or current meningeal metastasis are not eligible for enrollment.\n2. Start the study if the patient has received systemic anti-tumor treatment within 28 days prior to enrollment. If the patient has previously received small molecule targeted therapy, there must be an interval of at least 5 half-lives of that drug or 14 days, whichever is shorter, between the end of treatment and the first study treatment. If the patient has previously received traditional Chinese medicine or Chinese patent medicine for anti-tumor treatment, they may be enrolled if there is an interval of at least 14 days between the end of treatment and the first study treatment.\n3. Palliative radiotherapy completed within 14 days before the first administration.\n4. Unable to recover from the toxicity and\u002For complications of prior interventions to CTCAE ≤ Grade 1 (excluding conditions such as alopecia, Grade 2 peripheral neuropathy, and other situations deemed by the investigator not to affect the treatment with the investigational drug that meet the numerical requirements in the enrollment criteria).\n5. Used strong CYP3A4 inhibitors and P-gp, BCRP inhibitors within 7 days prior to the first administration, or used strong CYP3A4 inducers within 14 days prior to the first administration.\n6. Subjects with known or suspected interstitial pneumonia; those with significant pulmonary diseases impacting respiratory function in the three months prior to the first administration, including but not limited to idiopathic pulmonary fibrosis, organizing pneumonia\u002Fobliterative bronchiolitis, pulmonary embolism, severe asthma, severe COPD, moderate to severe obstructive\u002Frestrictive ventilatory dysfunction, or those with a history of undergoing total lung resection. Subjects who previously had grade 3 or higher interstitial pneumonia during treatment with immune checkpoint inhibitors are not allowed to enroll in this study.\n7. Patients with serious cardiovascular and cerebrovascular diseases.\n8. Patients with a history of or concurrent other malignant tumors, unless they have achieved complete remission for at least 5 years prior to screening and do not require other treatment for basal cell carcinoma or squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, local prostate cancer after radical surgery, or ductal carcinoma in situ after radical surgery during the study period (hormonal treatment for non-metastatic prostate cancer or breast cancer is allowed).\n9. Subjects who experienced severe infections within 28 days prior to the first dose of medication, including but not limited to infections requiring hospitalization, bacteremia, severe pneumonia, etc.; active infections treated with therapeutic intravenous antibiotics within 2 weeks prior to the start of study treatment.\n10. Those with active pulmonary tuberculosis infection within 1 year before enrollment, or those with a history of active pulmonary tuberculosis infection over 1 year ago but have not received formal treatment.\n11. Presence of active hepatitis B (HBV DNA above the normal upper limit of the research center or ≥ 2000 IU\u002FmL) or hepatitis C (anti-HCV positive and HCV RNA above the lower limit of the analysis method); presence of active syphilis infection.\n12. Live attenuated vaccine used within 28 days prior to the first administration of the study drug, or expected to use live attenuated vaccine during the anticipated treatment period.\n13. Patients with a history of immune deficiency diseases, including positive HIV tests, other acquired or congenital immune deficiency diseases, and those with a history of allogeneic hematopoietic stem cell transplantation or organ transplantation.\n14. Patients with third space fluid accumulation that cannot be controlled clinically, deemed unsuitable for enrollment by the investigator.\n15. Patients with refractory nausea and vomiting, chronic gastrointestinal diseases, etc., leading to an inability to swallow HRS-7058, or with intestinal obstruction, undergoing intestinal resection, etc., leading to insufficient absorption of HRS-7058.\n16. Patients who had significant clinically meaningful bleeding symptoms within 3 months before the first study medication, and those who had noticeable hemoptysis within 1 month before the first study medication with each episode of hemoptysis being ≥ 2.5 ml.\n17. Patients who have undergone other major surgeries excluding diagnosis or biopsy within 28 days prior to the first administration; those who have experienced traumatic minor surgeries (biopsy, endoscopy, and drainage) within 7 days prior to the first administration; patients with non-healing wounds (severe, non-healing or ruptured) or untreated fractures.\n18. Women who are pregnant or breastfeeding (even if the subject's blood pregnancy test is negative, if the researcher considers the subject's other circumstances and believes there may be a possibility of pregnancy, they need to be excluded; breastfeeding women are also not allowed to stop breastfeeding in order to participate in this study).\n19. Patients known to be allergic to any component of HRS-7058; patients with a known history of severe allergic reactions to the combined therapeutic antitumor drugs.\n20. Patients with uncontrollable mental illnesses as well as known situations of alcoholism, drug abuse or misuse, and criminal detention that affect the completion of the research procedures.\n21. According to the investigators' judgment, patients who may have other conditions that could increase the risk of participating in the study, interfere with the research results, or make them unsuitable for participation in this study.",{"count":435,"type":23},[114],"This study aims to evaluate the safety and tolerability of HRS-7058 combined with antitumor drugs in subjects with solid tumors, and to determine the recommended dosage for Phase II. Evaluate the objective response rate of HRS-7058 in combination with anti-tumor drugs in subjects with solid tumors.",[477],"Solid Tumors",{"date":479,"type":34},"2026-03-20",{"date":481,"type":34},"2025-07-09",{"date":483,"type":23},"2027-07",{"name":40,"class":41},{"id":486,"slug":487,"hasResults":12,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":175,"minAge":19,"maxAge":110,"enrollmentInfo":492,"targetDuration":4,"studyType":24,"phases":494,"briefSummary":495,"conditions":496,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":502,"leadSponsor":504,"locationsCount":126},"100568270","phase-1-a-trial-of-hrs-2189-in-combination-with-fluvastatinhrs-6209-or-hrs-8080hrs-6209-or-hrs-6209hrs-1358-in-breast-cancer-patients-100568270","NCT06679036","A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients","An Open, Multicenter Phase Ib\u002FII Clinical Study on the Safety, Tolerance, Pharmacokinetics, and Initial Efficacy of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Patients With Advanced Unresectable or Metastatic Breast Cancer","Inclusion Criteria:\n\n1. ECOG physical condition 0-1 point.\n2. Advanced unresectable or metastatic breast cancer confirmed by histopathology or cytopathology.\n3. Menopausal Status.\n4. Previous treatments: (New) adjuvant endocrine therapy combined or not combined with CDK4\u002F6 inhibitors during or within 12 months after treatment, including recurrence\u002Fmetastasis, shall be counted as one line of endocrine therapy and one line of CDK4\u002F6 inhibitor therapy (such as combined CDK4\u002F6 inhibitors); Relapse\u002Fmetastasis during (new) adjuvant chemotherapy or within 6 months after the end of treatment (whichever occurs later), counted as one line of chemotherapy.\n5. Disease progression confirmed by imaging during or after the last systemic anti-tumor treatment before the first use of medication (limited to the stage of efficacy expansion).\n6. There must be at least one measurable extracranial lesion that meets RECIST v1.1 at baseline.\n7. Expected survival\\>3 months.\n8. The functional level of 8 organs is good.\n9. Previous treatments: The interval between receiving nitrosourea or mitomycin C before the first medication in this study was ≥ 6 weeks; Receiving cytotoxic drugs, endocrine therapy, immunotherapy, targeted therapy, surgical interval (excluding biopsy or PICC catheterization or PORT infusion port catheterization surgery), or other clinical studies with the last dose of medication ≥ 4 weeks; The interval between the end of radiotherapy is ≥ 2 weeks.\n10. female participants with fertility must agree to use efficient contraceptive measures for contraception during the study treatment period and within 7 months after the end of the study treatment period; Female subjects with fertility must have a negative serum HCG test within 7 days prior to enrollment in the study and must be non lactating.\n11. Voluntarily participate in this clinical trial, willing and able to comply with the clinical visit and research related procedures, understand the research procedures, and have signed informed consent.\n\nExclusion Criteria:\n\n1. Patients with active (uncontrolled or symptomatic) brain metastases, cancerous meningitis, spinal cord compression, or a history of primary CNS tumors; patients with brain metastases who have completed treatment at least 28 days prior to first use of the study drug and are asymptomatic can be considered for enrollment if they have been confirmed asymptomatic by cranial imaging studies such as CT, MRI, or venography without evidence of cerebral hemorrhage, and have completed treatment at least 28 days before the first use of the study drug.\n2. Patients with a history of severe cardiovascular disease, including: (1) Congestive heart failure (NYHA Class\\>2); (2) Severe\u002Funstable angina, new angina within the last 3 months; (3) Myocardial ischemia requiring long-term medication control; patients with NYHA Class III-IV heart failure; (4) Acute myocardial infarction within the last 6 months; (5) Any grade 2 or higher supraventricular or ventricular arrhythmia that requires treatment or intervention; (6) Atrial fibrillation, coronary\u002Fperipheral artery bypass grafts, or cerebrovascular symptoms including transient ischemic attacks.\n3. Patients with factors affecting oral medication intake, such as difficulty swallowing or intestinal obstruction, or have active gastrointestinal diseases or other diseases that may significantly affect drug absorption, distribution, metabolism, or excretion (active inflammatory bowel disease or chronic diarrhea, enterocolitis or upper gastrointestinal surgery, including gastrectomy).\n4. Patients with uncontrollable third space effusions (such as large ascites, pleural effusion, pericardial effusion) or cancerous lymphedema.\n5. Pregnant women, nursing mothers, or those planning to become pregnant during the study period.\n6. Patients with significant liver disease history, untreated active hepatitis B (defined as positivity for HBsAg or HBcAb and HBV-DNA levels above the normal upper limit), or active hepatitis C (defined as HCV-RNA levels above the detection limit).\n7. Patients with uncontrolled chronic systemic comorbidities (such as severe chronic lung, liver, kidney or heart diseases).\n8. Patients with active autoimmune diseases, history of immune deficiency, autoimmune disease history, or history of diseases or syndromes requiring systemic corticosteroid hormones or immunosuppressive drug therapy, or have acquired (HIV infection) or congenital immunodeficiency diseases, or have a history of organ transplantation (including homologous bone marrow transplantation).\n9. Patients with active infectious tuberculosis and need for antimicrobial treatment.\n10. Patients with known significant liver disease history, untreated active hepatitis B (defined as positivity for HBsAg or HBcAb and HBV-DNA levels above the normal upper limit), or active hepatitis C (defined as HCV-RNA levels above the detection limit).\n11. Patients who have had other malignancies within the past 5 years, except: 1) Completely cured skin basal cell carcinoma and cervical intraepithelial neoplasia; 2) Completely cured and without recurrence of secondary primary cancer within 5 years.\n12. Patients who have used strong or moderate inhibitors of CYP3A4 within 1 week before the first dose or strong or moderate inducers of CYP3A4 within 2 weeks before the first dose.\n13. Pregnant women, nursing mothers, or those planning to become pregnant during the study period.\n14. Patients with a history of neurological or psychiatric disorders, or those with a history of abuse of psychotropic drugs or drug addiction.\n15. Patients who are expected to receive other anti-tumor treatments or medications during this study.\n16. Patients with other serious physical or laboratory abnormalities that may increase the risk of participating in the study or interfere with study results, and those deemed by the investigator not suitable for participation in this study.\n17. Patients with anti-tumor treatment-related toxicity in the past (excluding alopecia; according to the judgment of the investigator， after consultation with the sponsor, some tolerable chronic Grade II toxicities may be excluded).\n18. Patients who have an allergy to any study drug or any excipient.",{"count":493,"type":23},300,[26,114],"The study is being conducted to evaluate the efficacy, and safety of dexmedetomidine hydrochloride nasal spray for preoperative sedation in adults. To explore the reasonable dosage of dexmedetomidine hydrochloride nasal spray for preoperative sedation.",[497],"Advanced Unresectable or Metastatic Breast Cancer","2026-02-27",{"date":500,"type":34},"2026-03-02",{"date":442,"type":34},{"date":503,"type":23},"2026-12-31",{"name":40,"class":41},{"id":506,"slug":507,"hasResults":12,"nctId":508,"briefTitle":509,"officialTitle":510,"acronym":4,"eligibilityCriteria":511,"healthyVolunteers":12,"sex":175,"minAge":19,"maxAge":110,"enrollmentInfo":512,"targetDuration":4,"studyType":24,"phases":514,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":525,"locationsCount":126},"100594801","phase-3-a-phase-3-study-of-hrs-8080-versus-treatment-chosen-by-physicians-in-locally-advanced-and-metastatic-breast-cancer-100594801","NCT07024173","A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer","A Multicenter, Open-label, Randomized Controlled Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast Cancer With Disease Progression After Previous Endocrine Therapy","Inclusion Criteria:\n\n1. Women aged 18 to 75 years old (including both values).\n2. ECOG Physical Strength Status (PS) : 0 to 1 point.\n3. Patients with locally advanced or metastatic breast cancer confirmed by histology.\n4. Patients previously received 1-2 lines of endocrine therapy.\n5. Expected survival \\> 6 months.\n6. The functional level of the organs must meet the requirements.\n7. Subjects that voluntarily participate in this clinical trial, be willing and able to abide by the procedures related to clinical visits and research, understand the research procedures and have signed the informed consent.\n\nExclusion Criteria:\n\n1. Patients with rapid disease progress and investigators determine that endocrine therapy is not suitable or tolerant.\n2. A history of severe clinical cardiovascular diseases.\n3. Patients with uncontrollable tumor-related pain as judged by investigators.\n4. Severe infection exists within 4 weeks before the first study administration.\n5. Patients with clinically significant endometrial abnormalities.\n6. Untreated active hepatitis.\n7. Patients known to be allergic to HRS-8080 components.\n8. Pregnant and lactating women, or those planning to become pregnant during the study period.",{"count":513,"type":23},240,[157],"This study is a multicenter, open-label, randomized controlled Phase 3 clinical trial. It is planned to enroll 240 female patients with locally advanced or metastatic breast cancer followed by disease progression after previous endocrine therapy.",[517,518],"Locally Advanced Breast Cancer","Metastatic Breast Cancer","2026-01-22",{"date":521,"type":34},"2026-01-26",{"date":523,"type":34},"2025-07-23",{"date":247,"type":23},{"name":40,"class":41},""]